Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.37

Mkt cap

1.8M

Volume

605

High

0.37

P/E Ratio

-0.01

52-wk high

1.11

Low

0.37

Div yield

N/A

52-wk low

0.30

Panbela Therapeutics (NASDAQ:PBLA) is scheduled to release its quarterly earnings report on March 26, 2024, with an estimated EPS of $-24.34. Historical data shows mixed reactions to past earnings reports, with the last quarter missing EPS estimates and resulting in a 2.66% share price increase the following day. Over the past year, PBLA shares have declined by 99.79%, indicating significant investor concern ahead of this earnings announcement.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

The article highlights the top 4 oversold health care stocks with an RSI near or below 30, indicating potential undervaluation. These include ProSomnus, Inc. (OSA), Panbela Therapeutics, Inc. (PBLA), Sintx Technologies, Inc. (SINT), and GRI Bio, Inc. (GRI). Each company has experienced significant stock price declines recently but shows signs of potential short-term recovery.

Portfolio Pulse from Avi Kapoor

February 23, 2024 | 12:50 pm

Panbela Therapeutics announced it has regained compliance with Nasdaq's listing requirements, avoiding the risk of delisting.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:05 pm

In Wednesday's after-market session, several healthcare stocks showed notable movements. KalVista Pharma, Anitra, CytoMed Therapeutics, Vaccinex, Universe Pharmaceuticals, and Cidara Therapeutics were among the gainers, with increases ranging from 6.55% to 11.0%. On the losing side, Adaptive Biotechnologies, Beyond Air, Tenon Medical, Ontrak, Panbela Therapeutics, and Acutus Medical saw declines between 6.57% and 8.6%, with Adaptive Biotechnologies' drop attributed to its Q4 earnings release.

Portfolio Pulse from Benzinga Insights

February 14, 2024 | 9:31 pm

Roth MKM has reiterated a 'Buy' rating and a $25 price target for Panbela Therapeutics (PBLA), citing optimism from Ipsen's FDA approval of Onivyde for pancreatic cancer and Panbela's promising early phase results for SBP-101 for the same indication.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 7:52 pm

Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Panbela Therapeutics (NASDAQ:PBLA) and adjusted the price target to $25 from $500.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 7:12 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares dropped over 2% on Tuesday after a 65.3% decline on Monday. The company announced an abstract for SBP-101 was accepted for a poster presentation at the American Association for Cancer Research. Panbela is collaborating with Johns Hopkins University School of Medicine on this. Additionally, Panbela disclosed the pricing of a public offering of 4.38 million shares or pre-funded warrants, with two classes of warrants to purchase up to 8.75 million shares. The common warrants have an exercise price of $2.06 per share and are exercisable immediately, expiring in five years. The offering aims to raise approximately $9.0 million and is expected to close by January 31, 2024. Last week, Panbela was in news for enrolling in the ASPIRE global clinical trial for metastatic pancreatic cancer treatment.

Portfolio Pulse from Nabaparna Bhattacharya

January 30, 2024 | 2:56 pm

Panbela Therapeutics announced that an abstract for SBP-101 has been accepted for a poster presentation at the American Association for Cancer Research (AACR). The presentation will focus on the combination of Ivospemin/doxorubicin and its effects on polyamine metabolism in murine ovarian cancer models. The session is scheduled for April 10. The abstract number is 7154, and further details can be found on the AACR and Panbela's websites.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 1:18 pm

U.S. stocks saw a slight increase, with the Nasdaq Composite up by 75 points. The Dow and S&P 500 also experienced modest gains. Consumer discretionary shares led the gains, while energy shares declined following a 1.3% drop in crude oil prices. Science 37 Holdings (SNCE) surged 16% after agreeing to be acquired by eMed. SoFi Technologies (SOFI) jumped 16% on strong quarterly revenue, and Cardlytics (CDLX) rose 28% after a settlement agreement and updated Q4 results. Conversely, Panbela Therapeutics (PBLA) plummeted 67% due to a public offering, Bullfrog AI Holdings (BFRG) fell 24% after a shelf offering, and Bloom Energy (BE) dropped 7% after a downgrade by B of A Securities. The Federal Reserve Bank of Dallas reported a decline in Texas manufacturing activity.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:24 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) shares plummeted by 65.5% to $1.47 after announcing a public offering priced at approximately $9 million. Other stocks experienced significant movements in Monday's mid-day session, with various companies showing notable gains and losses. Gainers included Palisade Bio, Inc. (NASDAQ:PALI), OneMedNet Corporation (NASDAQ:ONMD), and Revelation Biosciences, Inc. (NASDAQ:REVB), among others. Losers featured SMX (Security Matters) Public Limited Company (NYSE:SMX), Inspire Veterinary Partners, Inc. (NASDAQ:IVP), and Bullfrog AI Holdings, Inc. (NASDAQ:BFRG), among others.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.